tiprankstipranks
Advertisement
Advertisement

RDHL Stock Latest News

RedHill Biopharma Reschedules 2026 AGM to Add Proposal, Seeks Approval to Scrap Par Value
Company AnnouncementsRedHill Biopharma Reschedules 2026 AGM to Add Proposal, Seeks Approval to Scrap Par Value
16d ago
6K
RDHL
RedHill Biopharma Expands ATM ADS Offering Capacity in U.S. Market
PremiumCompany Announcements
RedHill Biopharma Expands ATM ADS Offering Capacity in U.S. Market
18d ago
6K
RDHL
RedHill Biopharma Sets July 28, 2026 AGM to Vote on Board, Auditor and Chairman-CEO Role
PremiumCompany Announcements
RedHill Biopharma Sets July 28, 2026 AGM to Vote on Board, Auditor and Chairman-CEO Role
22d ago
6K
RDHL
RedHill Biopharma Closes $6 Million Private Placement to Fund Potential Acquisition
PremiumCompany Announcements
RedHill Biopharma Closes $6 Million Private Placement to Fund Potential Acquisition
25d ago
6K
RDHL
RedHill Biopharma Raises $6 Million in June 2026 Private Placement of ADSs and Warrants
PremiumCompany Announcements
RedHill Biopharma Raises $6 Million in June 2026 Private Placement of ADSs and Warrants
25d ago
6K
RDHL
RedHill Biopharma Sets July 28, 2026 Shareholder Meeting to Vote on Board, CEO-Chairman Role
PremiumCompany AnnouncementsRedHill Biopharma Sets July 28, 2026 Shareholder Meeting to Vote on Board, CEO-Chairman Role
25d ago
6K
RDHL
RedHill Biopharma Secures Up to $19.4 Million in Private Placement to Fund Pipeline and Potential Acquisition
Premium
Company Announcements
RedHill Biopharma Secures Up to $19.4 Million in Private Placement to Fund Pipeline and Potential Acquisition
29d ago
6K
RDHL
RedHill Biopharma announces $19.4M private placement
Premium
The Fly
RedHill Biopharma announces $19.4M private placement
29d ago
RDHL
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
PremiumMarket News
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
1M ago
GILD
JAZZ
RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst
PremiumMarket News
RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst
1M ago
GILD
RDHL
RedHill Biopharma Wins FDA Rare Pediatric Disease Designation for Opaganib in Neuroblastoma
PremiumCompany Announcements
RedHill Biopharma Wins FDA Rare Pediatric Disease Designation for Opaganib in Neuroblastoma
1M ago
6K
RDHL
RedHill Biopharma’s opaganib granted FDA Rare Pediatric Disease designation
PremiumThe Fly
RedHill Biopharma’s opaganib granted FDA Rare Pediatric Disease designation
1M ago
RDHL
RedHill Biopharma Moves to Enforce $10.9 Million New York Judgment Against Kukbo in Korea
PremiumCompany AnnouncementsRedHill Biopharma Moves to Enforce $10.9 Million New York Judgment Against Kukbo in Korea
1M ago
6K
RDHL
RedHill Biopharma launches enforcement of $11M judgment against Kukbo
Premium
The Fly
RedHill Biopharma launches enforcement of $11M judgment against Kukbo
1M ago
RDHL
RedHill Biopharma advancing opaganib options for Ebola outbreak biodefense
Premium
The Fly
RedHill Biopharma advancing opaganib options for Ebola outbreak biodefense
2M ago
RDHL
RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak
PremiumCompany Announcements
RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak
2M ago
6K
RDHL
RedHill Biopharma Expands At-The-Market ADS Offering to Boost Capital Flexibility
PremiumCompany Announcements
RedHill Biopharma Expands At-The-Market ADS Offering to Boost Capital Flexibility
2M ago
6K
RDHL
RedHill Biopharma Reports Promising MAP-Killing Data for Next-Generation Crohn’s Candidate RHB-204
PremiumCompany Announcements
RedHill Biopharma Reports Promising MAP-Killing Data for Next-Generation Crohn’s Candidate RHB-204
3M ago
6K
RDHL
RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease
PremiumThe Fly
RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease
3M ago
RDHL
RedHill Biopharma Reshapes Talicia Franchise and Strengthens Balance Sheet in 2025 Results
PremiumCompany AnnouncementsRedHill Biopharma Reshapes Talicia Franchise and Strengthens Balance Sheet in 2025 Results
3M ago
6K
RDHL
RedHill Biopharma announces presentation of preclinical data on opaganib at AACR
Premium
The Fly
RedHill Biopharma announces presentation of preclinical data on opaganib at AACR
3M ago
RDHL
RedHill Biopharma Showcases New Opaganib Preclinical Data in Neuroblastoma and Triple-Negative Breast Cancer at AACR 2026
Premium
Company Announcements
RedHill Biopharma Showcases New Opaganib Preclinical Data in Neuroblastoma and Triple-Negative Breast Cancer at AACR 2026
3M ago
6K
RDHL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >